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S u m m a r y  
 
The aim of the study was to assess the activation of 
extrinsic blood coagulation pathway, based on the TF and 
TFPI measurements in patients with MPNs. 
The study group consisted of 17 patients with MPNs 
(mean age 59 years). The control group was made of 30 
healthy volunteers (mean age 52 years). In blood samples 
tissue factor TF, tissue factor pathway inhibitor (TFPI), 
thrombin–antithrombin complexes (TAT) concentration and 
antithrombin (AT) activity were determined.  
The present study showed a significantly higher level of 
tissue factor and decreased TFPI concentration in patients 
with polycythemia vera, essential thrombocythemia and 
primary myelofibrosis. 
Conclusions: 
1. The results showed that in all groups of patients with 
MPNs an extrinsic activation of coagulation, resulting in a 
high concentration of TF in the blood of these patients, 
occurs. 
2. It seems that in patients with ET, PMF and PV, an 
extrinsic activation of coagulation is inhibited by TFPI 
inhibitor as evidenced by its reduced concentration observed 
in the blood of these patients (the result of extrinsic 
consumption in the track). 
 
 
S t r e s z c z e n i e  
 
Celem pracy była ocena aktywności krzepnięcia krwi 
drogą zewnątrzpochodną u chorych na przewlekłe 
nowotwory mieloproliferacyjne (PZM), na podstawie oceny 
stężenia czynnika tkankowego (TF) i inhibitora drogi 
zewnątrzpochodnej układu krzepnięcia (TFPI). 
Badaniami objęto grupę 17 chorych na PZM (kobiet i 
mężczyzn w średnim wieku 59 lat). Grupę kontrolną 
stanowiło 30 zdrowych ochotników, kobiet i mężczyzn w 
średnim wieku 52,4 lat. W cytrynianowej krwi żylnej 
oznaczono stężenie TF, całkowitej puli TFPI, stężenie 
kompleksów TAT oraz aktywności AT. 
Stwierdzono we krwi chorych na PZM istotnie 
podwyższone stężenie TF, a obniżone stężenie TFPI u 
chorych na CzP, NS i MF.  
Wnioski: 
1. Przeprowadzone badania wykazały, że we wszystkich 
grupach chorych z PZM występuje aktywacja krzepnięcia 
drogą zewnątrzpochodną, czego wyrazem jest wysokie 
stężenie TF we krwi tych chorych. 
2. Wydaje się, że u chorych na NS, MF i CzP aktywacja 
układu krzepnięcia drogą zewnątrzpochodną jest hamowana 
przez inhibitor TFPI, o czym może świadczyć obniżone jego 
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stężenie obserwowane we krwi tych chorych (wynik zużycia w torze zewnątrzpochodnym). 
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The first formal classification of myeloproliferative 
diseases was proposed in 1951 by William Dameshek. 
Dameshek’s concept assumed that these diseases result 
from the disturbances of mechanisms regulating 
normal hematopoiesis.  
Myeloproliferative neoplasms (MPNs) are clonal 
hematopoietic stem cell disorders, characterized by 
proliferation in the bone marrow of one or more of the 
myeloid (granulocytic, erythroid, mast cell and 
megakaryocytic) lineages [1].  
MPNs are now classified into eight categories:  
1) chronic myeloid leukemia (CML) 
2)  polycythemia vera (PV) 
3) essential thrombocythemia (ET) 
4) primary myelofibrosis (PMF) 
5) systemic mastocytosis (SM) 
6)  chronic eosinophilic leukemia (CEL) not 
otherwise specified 
7)  chronic neutrophilic leukemia (CNL) 
8)  unclassifiable MPNs. 
MPN-unclassifiable is a group of MPN-like 
disorders that do not meet the diagnostic criteria for 
either the classic or non-classic MPNs. 
MPNs have a number of common features in the 
etiology, pathogenesis, clinical presentation, and 
treatment. In myeloproliferative neoplasms occurs 
clonal proliferation of all hemopoietic cell lines, of 
which the dominant one determines the type of disease. 
Clonal nature of hematopoiesis in MPNs was 
confirmed by the results of the studies concerning the 
isoenzymes of glucose-6-phosphate dehydrogenase (G-
6-PD). In heterozygous patients with 
myeloproliferative neoplasms in all somatic cells were 
observed two isoenzymes of G-6-PD (A and B), but in 
hematopoietic cells only one of them (type A or B). 
The loss of one isoenzyme started in multipotent stem 
cells, and then as a result of proliferation took up all 
the hematopoietic cells. Moreover, cytogenetic and 
molecular studies in chronic myeloid leukemia (CML) 
confirm the presence of the Ph chromosome and BCR-
ABL fusion gene, which encodes a P 210 protein 
responsible for the malignant transformation [2]. 
Recent studies indicate the presence of a JAK2 
mutation in patients with PV, ET and mutations in 
gene 10 (on chromosome X) as well as 11-13 in 
patients with PMF [3, 4]. 
In patients with MPNs are observed frequent 
hemostatic disturbances such as thrombotic disease and 
bleeding disorder. 
Recent reports indicate that the major and the most 
important pathway of coagulation is the extrinsic 
coagulation pathway, in which the key role plays a 
tissue factor (TF) and factor VII [5]. Data on the TF 
concentration in cancer are divergent, but there is 
single report, which indicates increased level of TF in 
patients with myeloproliferative diseases [6]. 
The major endogenous regulator of coagulation 
activation dependent on TF is tissue factor pathway 
inhibitor (TFPI). TFPI inhibits the activity of factor Xa 
and the complex of factor VIIa / TF. In neoplasms the 
concentration of coagulation inhibitors such as TFPI 
may be normal or elevated with reduced its activity at 
the same time. 
Thromboembolism and bleeding are one of the 
most common causes of death in patients with 
proliferative diseases.  
Experimental studies on animals as well as clinical 
researches provide information about relationship 
between blood coagulation system and tumor growth. 
It is well known that hemostatic disturbances are 
secondary to the cancer and usually develop as the 
disease progresses. There are no ideal parameters, 
which allow assessing the risk of thrombotic disease 
and bleeding disorder. Well established laboratory tests 
have poor diagnostic and prognostic value. For this 
reason, hemostatic disturbances observed in cancer 
patients are still important clinical problem.  
The aim of the study was to assess the activation of 
extrinsic blood coagulation pathway, based on the TF 
and TFPI measurements in patients with MPNs. 
 
MATERIAL AND METHODS 
 
The study group consisted of 17 patients with 
myeloproliferative neoplasms (mean age 59), treated in 
the Clinic of Haematology, Dr Jan Biziel University 
Hospital No. 2 in Bydgoszcz. Based on medical 
interview, physical examination and additional tests 
(complete blood count with peripheral blood smear, 
selected parameters of coagulation system, bone 
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marrow biopsy with histopathological evaluation and 
cytogenetic) the diagnosis of MPNs was made. None 
of the patients had clinical symptoms of thrombotic 
disease and hemorrhagic diathesis at the time of blood 
collection.  
The control group consisted of 30 healthy 
volunteers, age- and sex- matched (mean age 52). The 
study obtained the approval of the local Ethics 
Committee. Each studied person was informed about 
the purpose of the research and gave written consent. 
Blood samples were drawn from an antecubital 
vein (in the morning) into a plastic tube containing 
3.2% sodium citrate (anticoagulant: blood - 1:9). Then 
the samples were centrifuged at 3000 rev/min for 15 
minutes at 4°C. The obtained plasma was divided into 
aliquots and stored at -80°C until analysis. 
In the blood collection day the following 
parameters were determined:  
1. complete blood count with peripheral blood 
smear 
2. In the platelet-poor plasma the following 
parameters were measured using ELISA 
technique: 
3. tissue factor concentration (TF)  
4. tissue factor pathway inhibitor (TFPI)  
5. level of thrombin-antithrombin complexes 
(TAT) with American Diagnostica kits 
6. antithrombin activity (AT) (Dade Behring kit) 
using chromogenic method. 
Analysed variables were examined statistically 
(using STATISTICA for Windows) on account of 
the compliance with the normal distribution. 
Kolmogorov-Smirnov test was used to assess the 
normality of the distribution. Data are presented as 
mean and standard deviation for normally 
distributed continuous variables and were measured 
by Student’s t-test. Values of p<0.05 were 




Table I shows the mean and standard deviation of 
TF and TFPI concentration in patients with neoplasms 
and in the control group. As shown, in all 
myeloproliferative neoplasms was significantly 
increased TF concentration in comparison to the 
controls. TFPI concentration was significantly elevated 
in patients with CML, and decreased in the other 
MPNs. 
Table I. Plasma levels of TF and TFPI in patients with 
myeloproliferative neoplasms in comparison to the 
control group 
Tabela I. Stężenie TF i TFPI w osoczu chorych na PZM w 























































Table II. Concentration of TAT complexes and AT activity in 
patients with myeloproliferative neoplasms in 
comparison to the control group 
Tabela II. Stężenie kompleksów TAT i aktywności AT w 

























































Table II contains the average value and the standard 
deviation of antithrombin (AT) and thrombin-
antithrombin complexes (TAT) in the study group and 
controls. The highest average value of TAT 
concentration was observed in patients with PV and 





Present study has shown that in patients with ET, 
PV there is a significant increase of TF concentration 
as well as a decrease in TFPI level in comparison to 
controls. However, clear interpretation in CML and 
PMF patients is impossible due to the small size of the 
group.  
Tissue factor, also known as a thromboplastin is a 
cellular receptor of factor VII. The extrinsic 
coagulation pathway begins by the binding of  factor 
VII to TF produced by subendothelial cells. The 
resulting complex (TF/VIIa) activates factor X, which 
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leads to thrombin generation and, ultimately, initiates 
the process of fibrin formation [7]. In  thrombotic 
process in patients with PV and ET are involved: JAK2 
mutation, tissue factor expression, circulating 
microparticles, increased blood viscosity, leucocyte 
activation and their interactions with platelets and 
endothelial cells [8]. 
In the available literature there were not any reports 
concerning TF in myeloproliferative neoplasms. 
Takahashii et al. showed increased levels of TF in 
proliferative diseases of the hematopoietic system [9]. 
High TF concentration in patients with acute myeloid 
leukemia may reflect an increased procoagulant 
readiness [10]. Other studies have demonstrated  that 
changes in TF concentration in patients with acute 
promyelocytic leukemia were not statistically 
significant; furthermore there was no correlation 
between the concentration and activity of TF [6,11].  
The next parameter evaluated in patients with 
MPNs was TFPI concentration. TFPI is a specific 
inhibitor of coagulation pathway initiated by TF. This 
inhibitor is bound to either endothelial cells or 
lipoproteins and it can also exist as a free TFPI fraction 
[12]. TFPI which consists of 276 amino acides, can 
effectively inhibit TF/FVIIa complexes, as well as 
factor Xa (FXa). TFPI is synthesized mainly by 
endothelial cells and for this reason contributes to the 
antithrombotic potential of the vascular endothelium 
[7]. 
In our study it was found that in patients with ET, 
PMF and PV the TFPI concentration is lowered. This 
may be a result of its consumption in the coagulation 
pathway. 
The analysis of literature shows that so far there has 
been only sporadic research concerning TFPI 
concentration in patients with hematologic 
malignancies. Mazgajska et al. and Radziwon et al.  
showed elevated level of  TFPI in patients with 
hematologic malignancies [6, 13]. In patients with 
acute myeloid leukemia with a course complicated by 
disseminated intravascular coagulation  there was 
observed a low concentration and activity of TFPI [6, 
14]. 
Antithrombin is a plasmin coagulation inhibitor, 
which inactivates thrombin - a key enzyme in the 
coagulation process. The consequence of this process 
is the formation of inactive thrombin-antithrombin 
complexes (TAT). Concentration of TAT complexes 
shows intravascular  thrombinogenesis. Research 
indicates that an increase in TAT concentration is a 
sensitive and authoritative indicator of ongoing 
thrombotic process.  
The study showed that in patients with 
myeloproliferative neoplasms was higher mean TAT 
concentration compared to the control group, however 
due to the  wide range of individual values and small 
number of patients, the difference was not statistically 
significant. The mean AT activities in patients with ET 
and PV were higher than in the control group, but the 
differences were not statistically significant. Research 
is being continued on a larger number of patients with 





1. The results showed that in all groups of patients 
with MPNs an extrinsic activation of coagulation, 
resulting in a high concentration of TF in the blood of 
these patients occurs. 
2. It seems that in patients with ET, PMF and PV, 
an extrinsic activation of coagulation is inhibited by 
TFPI inhibitor as evidenced by its reduced 
concentration  observed in the blood of these patients 
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